Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Payables: 2012-2025

Historic Payables for Agios Pharmaceuticals (AGIO) over the last 13 years, with Sep 2025 value amounting to $19.6 million.

  • Agios Pharmaceuticals' Payables rose 14.06% to $19.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $67.5 million, marking a year-over-year increase of 40.20%. This contributed to the annual value of $16.6 million for FY2024, which is 70.17% up from last year.
  • According to the latest figures from Q3 2025, Agios Pharmaceuticals' Payables is $19.6 million, which was up 11.53% from $17.5 million recorded in Q2 2025.
  • Over the past 5 years, Agios Pharmaceuticals' Payables peaked at $51.2 million during Q1 2021, and registered a low of $7.7 million during Q2 2021.
  • Moreover, its 3-year median value for Payables was $13.3 million (2023), whereas its average is $13.6 million.
  • As far as peak fluctuations go, Agios Pharmaceuticals' Payables spiked by 173.82% in 2021, and later crashed by 77.45% in 2022.
  • Quarterly analysis of 5 years shows Agios Pharmaceuticals' Payables stood at $16.7 million in 2021, then increased by 11.47% to $18.6 million in 2022, then crashed by 47.46% to $9.8 million in 2023, then soared by 70.17% to $16.6 million in 2024, then rose by 14.06% to $19.6 million in 2025.
  • Its Payables was $19.6 million in Q3 2025, compared to $17.5 million in Q2 2025 and $13.7 million in Q1 2025.